Viracta Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2007-01-01
- Employees
- 40
- Market Cap
- $8.7M
- Website
- http://www.viracta.com
- Introduction
Viracta Therapeutics, Inc. a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. It develops antiviral agent valganciclovir as an oral combination therapy which is in a Phase 2 clinical trial for EBV-positive lymphomas. The company was founded on February 10, 1998 and is h...
A Mass Balance Study of [14C]-Nanatinostat and Relative Bioavailability Study of Nanatinostat in Patients With Advanced Cancers
- First Posted Date
- 2024-03-08
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- Viracta Therapeutics, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT06302140
- Locations
- 🇪🇸
START Madrid - CIOCC - Hospital Universitario HM Sanchinarro, Madrid, Spain
Nanatinostat Plus Valganciclovir in Patients With Advanced EBV+ Solid Tumors, and in Combination With Pembrolizumab in EBV+ RM-NPC
- Conditions
- Interventions
- First Posted Date
- 2021-12-22
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Viracta Therapeutics, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT05166577
- Locations
- 🇺🇸
Stanford Cancer Center, Stanford, California, United States
🇺🇸University of Colorado Hospital, Aurora, Colorado, United States
🇺🇸University of Texas MD Anderson Cancer Center, Houston, Texas, United States
An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas
- First Posted Date
- 2021-08-18
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Viracta Therapeutics, Inc.
- Target Recruit Count
- 140
- Registration Number
- NCT05011058
- Locations
- 🇺🇸
The University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸City of Hope, Duarte, California, United States
Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV-Associated Lymphoid Malignancies
- Conditions
- Interventions
- First Posted Date
- 2018-01-12
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Viracta Therapeutics, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT03397706
- Locations
- 🇺🇸
Georgia Cancer Center at Augusta University, Augusta, Georgia, United States
🇺🇸Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
🇺🇸University of California, Los Angeles, Los Angeles, California, United States
ABT-378/Ritonavir and Efavirenz in HIV-Infected Patients Who Have Taken More Than One Protease Inhibitor in the Past
- Conditions
- Locations
- 🇺🇸
ViRx Inc, San Francisco, California, United States